Date: 2015-08-05
Type of information: Licensing agreement
Compound: LJPC-30Sa, LJPC-30Sb
Company: La Jolla Pharmaceutical (USA - CA) The Indiana University Research and Technology Corporation (IURTC) (USA - IN) The University of Alabama at Birmingham (UAB) (USA - AL)
Therapeutic area: Infectious diseases - Genetic diseases - Rare diseases
Type agreement: licensing
Action mechanism: antibiotic. LJPC-30Sa and LJPC-30Sb are La Jolla’s next-generation gentamicin derivatives. Despite kidney toxicity, gentamicin has become one of the most commonly prescribed hospital antibiotics due to its broad spectrum of antimicrobial efficacy. Gentamicin consists primarily of a mixture of four distinct but closely related chemical entities that may contribute differentially to the product’s toxicity profile. LJPC-30Sa and LJPC-30Sb are purified components of the currently marketed gentamicin product that retain the biologic activity of gentamicin, yet appear to lack the traditional kidney toxicity associated with it. La Jolla is developing LJPC-30Sa and LJPC-30Sb not only for the potential treatment of serious bacterial infections but also for the potential treatment of rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.
Disease:
Details: * On August 5, 2015, La Jolla Pharmaceutical Company, a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, announced that it has signed two exclusive worldwide license agreements for the intellectual property rights covering La Jolla’s next-generation gentamicin derivatives, LJPC-30Sa and LJPC-30Sb. The first license agreement is with the Indiana University Research and Technology Corporation (IURTC), and the second is with the IURTC and the University of Alabama at Birmingham (UAB). The license agreements, which follow from the previously announced option agreements, cover the use of LJPC-30Sa and LJPC-30Sb as antimicrobial agents and for the potential treatment of rare genetic disorders. La Jolla plans to pursue a dual development strategy with its next-generation gentamicin derivative program. Specifically, La Jolla plans to develop LJPC-30Sa and LJPC-30Sb not only for the potential treatment of serious bacterial infections but also for the potential treatment of rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy. Following a pre-Investigational New Drug Application (IND) meeting with the FDA, La Jolla has received guidance that it may proceed with a proposed Phase 1 clinical trial following the submission of an IND.
Financial terms:
Latest news:
